RNA interference for studying the molecular basis of neuropsychiatric disorders

Current Opinion in Drug Discovery and Development

Volumn 10, Issue 2, 2007, Pages 122-129

  Hoyer, Daniel ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

dsRNA; Gene knockdown; Post transcriptional gene silencing; Psychiatric and neurodegenerative disorders; RNAi; shRNA; siRNA; Target validation; Therapy

Indexed keywords

ADENOVIRUS VECTOR; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANALGESIC AGENT; ATAXIN 1; BETA SECRETASE; COPPER ZINC SUPEROXIDE DISMUTASE; DOUBLE STRANDED RNA; EXPORTIN 5; HUNTINGTIN; KARYOPHERIN; MESSENGER RNA; N (4 TERT BUTYLPHENYL) 4 (3 CHLOROPYRIDIN 2 YL)TETRAHYDROPYRAZINE 1(2H) CARBOXAMIDE; NEUROPEPTIDE Y; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PRESENILIN 1; PRESENILIN 2; PRION PROTEIN; PROTEIN KINASE B; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TAU PROTEIN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST; VIRUS VECTOR;

ALLODYNIA; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTINOCICEPTION; BIOINFORMATICS; BRAIN CANCER; CELL STRAIN HEK293; CENTRAL NERVOUS SYSTEM; CHO CELL; CHROMOSOME 10; CHRONIC PAIN; DRUG EFFECT; DYSTONIA; ENCEPHALITIS; ENZYME RELEASE; FUNCTIONAL GENOMICS; GENE DELETION; GENE EXPRESSION; GENE LIBRARY; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; GUINEA PIG; HELA CELL; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; JAPANESE ENCEPHALITIS VIRUS; KENNEDY DISEASE; LIVER INJURY; MACHADO JOSEPH DISEASE; MOUSE STRAIN; MULTIGENE FAMILY; NERVE CELL DEGENERATION; NEUROPATHIC PAIN; NEUROPSYCHIATRY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PROMOTER REGION; REVIEW; RNA INTERFERENCE; SPINAL MUSCULAR ATROPHY; SPINOCEREBELLAR DEGENERATION; VISCERAL PAIN; WEST NILE FLAVIVIRUS;

ANIMALS; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM INFECTIONS; GENE LIBRARY; GENE SILENCING; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PAIN; RNA INTERFERENCE; VIRUS DISEASES;

EID: 33947306928     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391(6669):806-811. •• The foundation paper describing that dsRNA has profound gene-silencing effects.
2. Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM: Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods (2006) 3(9):715-719. • A major effort to create publicly accessible genome-wide shRNA libraries
3. Chang K, Elledge SJ, Hannon GJ: Lessons from nature: MicroRNA-based shRNA libraries. Nat Methods (2006) 3(9):707-714.
4. Mukherji M, Bell R, Supekova L, Wang Y, Orth AP, Batalov S, Miraglia L, Huesken D, Lange J, Martin C, Sahasrabudhe S et al: Genome-wide functional analysis of human cell-cycle regulators. Proc Natl Acad Sci USA (2006) 103(40):14819-14824.
5. Yang JP, Fan W, Rogers C, Chatterton JE, Bliesath J, Liu G, Ke N, Wang CY, Rhoades K, Wong-Staal F, Li QX: A novel RNAi library based on partially randomized consensus sequences of nuclear receptors: Identifying the receptors involved in amyloid β degradation. Genomics (2006) 88(3):282-292.
6. Majercak J, Ray WJ, Espeseth A, Simon A, Shi XP, Wolffe C, Getty K, Marine S, Stec E, Ferrer M, Strulovici B, Bartz S et al: LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. Proc Natl Acad Sci USA (2006) 103(47):17967-17972.
7. Zhao TY, Zou SP, Alimova YV, Wang G, Hauser KF, Ghandour MS, Knapp PE: Short interfering RNA-induced gene silencing is transmitted between cells from the mammalian central nervous system. J Neurochem (2006) 98(5):1541-1550.
8. Koller E, Propp S, Murray H, Lima W, Bhat B, Prakash TP, Allerson CR, Swayze EE, Marcusson EG, Dean NM: Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res (2006) 34(16):4467-4476. • A study highlighting that exogeneous siRNAs compete for RISC, with many potentially negative consequences.
9. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 441(7092):537-541. • A further illustration of exogeneous siRNAs competing for the RISC and the resulting consequences.
10. Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJ, Martin P, Bevan S, Fox A, Ganju P, Wishart W, Hall J: siRNA relieves chronic neuropathic pain. Nucleic Acids Res (2004) 32(5):e49. •• The first paper to demonstrate in vivo effects of siRNA in pain models using functional readouts.
11. Luo MC, Zhang DQ, Ma SW, Huang YY, Shuster SJ, Porreca F, Lai J: An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol Pain (2005)1:29.
12. Tan PH, Yang LC, Shih HC, Lan KC,Cheng JT: Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther (2005) 12(1):59-66.
13. Guo W, Robbins MT, Wei F, Zou S, Dubner R, Ren K: Supraspinal brain-derived neurotrophic factor signaling: A novel mechanism for descending pain facilitation. J Neurosci (2006) 26(1):126-137.
14. Christoph T, Grunweller A, Mika J, Schafer MK, Wade EJ, Weihe E, Erdmann VA, Frank R, Gillen C, Kurreck J: Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Biophys Res Commun (2006) 350(1):238-243.
15. V1.8 alleviates experimentally-induced chronic pain. Abstr Soc Neurosci (2006):245.11/N10.
16. Porreca F: Targeting neuropathic pain with RNA interference: Validation of molecular mechanism and therapeutics. Abstr Soc Neurosci (2006):Abs 299.5.
17. Hoyer D, Thakker DR, Natt F, Maier R, Huesken D, Müller N, Flor P, van der Putten H, Schmutz M, Bilbe G, Cryan JF: Global down-regulation of gene expression in the brain using RNA interference, with emphasis on monamine transporters and GPCRs: Implications for target characterization in psychiatric and neurological disorders. J Recept Signal Transduct Res (2006) 26(5-6):527-547.
18. Fendt M, Siegl S, Schmid S, Thakker DR, Jacobson LH, YamamotoR, Mitsukawa K, Maier R; Kelly PH, McAllister KH, Hoyer D, van der Putten PH, Cryan JF, Flor PJ: mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity. Abstr Soc Neurosci (2006):Abs 370.15.
19. Thakker DR, Natt F, Maier R, Müller M, van der Putten H, Hoyer D, Cryan JF: Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA (2004) 101(49):17270-17275. •• The first paper documents brain-wide downregulation of genes using siRNA and the behavioral consequences thereof by using multiple behavioral readouts.
20. Thakker DR, Natt F, Husken D, van der Putten H, Maier R, Hoyer D, Cryan JF: siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol Psychiatry (2005) 10(8):782-789.
21. Thakker DR, Hoyer D, Cryan JF: Interfering with the brain: Use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders. Pharmacol Ther (2006) 109(3):413-438.
22. Salahpour A, Medvedev IO, Beaulieu JM, Gainedinov RR, Caron MG: Local knockdown of genes in the brain using small interfering RNA: A phenotypic comparison with knockout animals. Biol Psychiatry (2007) 61(1):65-69.
23. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA (2005) 102(16):5820-5825. •• An important milestone in the application of RNA interference to animal models of neurodegeneration (see references [24•] and 26•]).
24. Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ: Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther (2005) 12(4):618-633. • A further milestone in the application of RNA interference to animal models of neurodegeneration (see references [23••] and [26•]).
25. Machida Y, Okada T, Kurosawa M, Oyama F, Ozawa K, Nukina N: rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun (2006) 343(1):190-197.
26. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E: Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci (2005) 8(10):1343-1349. • A further milestone in the application of RNA interference to animal models of neurodegeneration (see references [23••] and [24•]).
27. Hong CS, Goins WF, Goss JR, Burton EA, Glorioso JC: Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-β peptide in vivo. Gene Ther (2006) 13(14):1068-1079.
28. Feng X, Zhao P, He Y, Zuo Z: Allele-specific silencing of Alzheimer's disease genes: The amyloid precursor protein genes with Swedish or London mutations. Gene (2006) 371(1):68-74.
29. Gonzalez-Alegre P, Bode N, Davidson BL, Paulson HL: Silencing primary dystonia: Lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci (2005) 25(45):10502-10509. • This paper suggests that allele-specific gene regulation can be achieved with RNAi.
30. Gonzalez-Alegre P: Therapeutic RNA interference for inherited dystonia. Abstr Soc Neurosci (2006):Abs 299.5
31. Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, Wong LF, Bisland LG, Greensmith L, Kingsman SM, Mitrophanous KA, Mazarakis ND, Azzouz M: Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med (2005) 11(4):429-433
32. Raoul C Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, Henderson CE, Aebischer P: Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med (2005) 11(4):423-428.
33. Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, Burchard J, Linsley PS, Aronin N, Xu Z, Zamore PD: Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet (2006) 2(9):e140.
34. Xia X, Zhou H, Huang Y, Xu Z: Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis (2006) 23(3):578-586.
35. Pallini R, Sorrentino A, Pierconti F, Maggiano N, Faggi R, Montano N, Maira G, Larocca LM, Levi A, Falchetti ML: Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. Int J Cancer (2006) 118(9):2158-2167.
36. Kumar P, Lee SK, Shankar P, Manjunath N: A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med (2006) 3(4):e96.
37. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC et al: Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis (2006)193(12): 1650-1657. •• RNAi is demonstrated to protect from the lethal Ebola virus in vivo.
38. Guerciolini R: Clinical update on Sirna-27. Second Annual Meeting of the Oligonucleotide Therapeutics Society, New York, NY, US (2006).
39. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD et al: RNAi-mediated gene silencing in non-human primates. Nature (2006) 441(7089):111-114.